BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8790203)

  • 1. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain.
    Quirijnen JM; Han SH; Zonnenberg BA; de Klerk JM; van het Schip AD; van Dijk A; ten Kroode HF; Blijham GH; van Rijk PP
    J Nucl Med; 1996 Sep; 37(9):1511-5. PubMed ID: 8790203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
    Han SH; de Klerk JM; Tan S; van het Schip AD; Derksen BH; van Dijk A; Kruitwagen CL; Blijham GH; van Rijk PP; Zonnenberg BA
    J Nucl Med; 2002 Sep; 43(9):1150-6. PubMed ID: 12215552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 186Re-etidronate in breast cancer patients with metastatic bone pain.
    Han SH; Zonneberg BA; de Klerk JM; Quirijnen JM; van het Schip AD; van Dijk A; Blijham GH; van Rijk PP
    J Nucl Med; 1999 Apr; 40(4):639-42. PubMed ID: 10210223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
    de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Quirijnen JM; Blijham GH; van Rijk PP
    J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
    Kolesnikov-Gauthier H; Carpentier P; Depreux P; Vennin P; Caty A; Sulman C
    J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
    Palmedo H; Manka-Waluch A; Albers P; Schmidt-Wolf IG; Reinhardt M; Ezziddin S; Joe A; Roedel R; Fimmers R; Knapp FF; Guhlke S; Biersack HJ
    J Clin Oncol; 2003 Aug; 21(15):2869-75. PubMed ID: 12885803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
    Han SH; De Klerk JM; Zonnenberg BA; Tan S; Van Rijk PP
    Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
    De Klerk JM; Zonnenberg BA; Blijham GH; Van Het Schip AD; Hoekstra A; Han SH; Quirijnen JM; Van Dijk A; Van Rijk PP
    Anticancer Res; 1997; 17(3B):1773-7. PubMed ID: 9179233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
    de Klerk JM; van Dijk A; van het Schip AD; Zonnenberg BA; van Rijk PP
    J Nucl Med; 1992 May; 33(5):646-51. PubMed ID: 1373767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
    de Klerk JM; van Dieren EB; van het Schip AD; Hoekstra A; Zonnenberg BA; van Dijk A; Rutgers DH; Blijham GH; van Rijk PP
    J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
    de Klerk JM; Zonnenberg BA; Krouwer HG; Blijham GH; van Dijk A; van het Schip AD; van Die J; van Rijk PP
    J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
    Klutmann S; Bohuslavizki KH
    MMW Fortschr Med; 1999 Nov; 141(44):38-9. PubMed ID: 10912142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
    Maxon HR; Schroder LE; Hertzberg VS; Thomas SR; Englaro EE; Samaratunga R; Smith H; Moulton JS; Williams CC; Ehrhardt GJ
    J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
    de Klerk JM; van het Schip AD; Zonnenberg BA; van Dijk A; Stokkel MP; Han SH; Blijham GH; van Rijk PP
    J Nucl Med; 1994 Sep; 35(9):1423-8. PubMed ID: 8071686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F; Herberg A; Spadaro P; Restifo Pecorella G; Baldari S; Aricò D; Altavilla G; Baldari S
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):355-62. PubMed ID: 17043634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palliative radiation with a radiolabeled diphosphonate (rhenium-186 etidronate) in patients with hormone-refractory disseminated prostate carcinoma.
    Tennvall J; Abrahamsson PA; Ahlgren G; Darte L; Flodgren P; Garkavij M; Strand SE
    Scand J Urol Nephrol; 2000 Jun; 34(3):188-93. PubMed ID: 10961473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosage and response in radiopharmaceutical therapy of painful osseous metastases.
    Silberstein EB
    J Nucl Med; 1996 Feb; 37(2):249-52. PubMed ID: 8667054
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
    de Klerk JM; Zonnenberg BA; van het Schip AD; van Dijk A; Han SH; Quirijnen JM; Blijham GH; van Rijk PP
    Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases.
    Palmedo H; Guhlke S; Bender H; Sartor J; Schoeneich G; Risse J; Grünwald F; Knapp FF; Biersack HJ
    Eur J Nucl Med; 2000 Feb; 27(2):123-30. PubMed ID: 10755716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.